AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A compound comprising an oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising an at least 8 consecutive nucleobase portion of SEQ ID NO: 64, wherein said nucleobase sequence of said oligonucleotide is 100% complementary to SEQ ID NO:17 as measured over the entirety of said oligonucleotide.

2. (Previously Presented) The compound of claim 1, wherein said oligonucleotide is an antisense oligonucleotide.

3. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

4. (Original) The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

5. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

6. (Previously Presented) The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety or a 4'- $(CH_2)_n$-O-2' bridge, wherein n is 1 or 2.

7. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

8. (Original) The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.

9. (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

10. (Canceled).

11. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

12. (Original) The composition of claim 11 further comprising a colloidal dispersion system.

13. (Previously Presented) The composition of claim 11 wherein the oligonucleotide is an antisense oligonucleotide.

14. (Previously Presented) A method of inhibiting the expression of BCL2-associated X protein in cells or tissues in vitro comprising contacting said cells or tissues with the compound of claim 1 such that expression of BCL2-associated X protein is inhibited.

15. (Previously Presented) The compound of claim 1 wherein the compound comprises ISIS 134323.

16. (Previously Presented) The compound of claim 1 wherein the compound consists of SEQ ID NO: 64.

17. (Previously Presented) The compound of claim 2 wherein the oligonucleotide comprises:

a gap segment consisting of linked deoxynucleotides;

a 5' wing segment consisting of linked nucleotides;

a 3' wing segment consisting of linked nucleotides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleotide of each wing segment comprises a modified sugar.

18. (Previously Presented) The compound of claim 17 wherein the oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleotides;

a 5' wing segment consisting of five linked nucleotides;

a 3' wing segment consisting of five linked nucleotides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleotide of each wing segment comprises a 2'-O-methoxyethyl sugar, wherein each cytosine in said oligonucleotide is a 5-methylcytosine and wherein each internucleoside linkage in said oligonucleotide is a phosphorothioate linkage.

19. (Previously Presented) The compound of claim 18, wherein said oligonucleotide is 20 nucleobases in length and consists of SEQ ID NO:64.

20. (Previously Presented) A compound comprising an oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising an at least 8 consecutive nucleobase portion of nucleobases 263-326 of SEQ ID NO:17, wherein said

nucleobase sequence of said oligonucleotide is 100% complementary to SEQ ID NO:17 as measured over the entirety of said oligonucleotide.

21. (Previously Presented) The compound of claim 20, consisting of a single-stranded modified oligonucleotide.

22. (Previously Presented) The compound of claim 21, wherein at least one internucleoside linkage is a modified internucleoside linkage.

23. (Previously Presented) The compound of claim 22, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

24. (Previously Presented) The compound of claim 21, wherein at least one nucleoside comprises a modified sugar.

25. (Previously Presented) The compound of claim 24, wherein at least one modified sugar is a bicyclic sugar.

26. (Previously Presented) The compound of claim 24, wherein at least one modified sugar comprises a 2'-O-methoxyethyl or a 4'- $(CH_2)_n$-O-2' bridge, wherein n is 1 or 2.

27. (Previously Presented) The compound of claim 21, wherein at least one nucleoside comprises a modified nucleobase.

28. (Previously Presented) The compound of claim 27, wherein the modified nucleobase is a 5-methylcytosine.

29. (Previously Presented) The compound of claim 20, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;

a 5' wing segment consisting of linked nucleosides;

a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

30. (Previously Presented) The compound of claim 29, wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides;

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; wherein each cytosine in said modified oligonucleotide is a 5-methylcytosine, and wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage.

31. (Previously Presented) The compound of claim 30, wherein the modified oligonucleotide consists of 20 linked nucleosides.

32. (Previously Presented) A composition comprising the compound of claim 20 or a salt thereof and a pharmaceutically acceptable carrier or diluent.

33. (Previously Presented) The composition of claim 32, wherein said modified oligonucleotide consists of a single-stranded oligonucleotide.

34. (Previously Presented) The composition of claim 32, wherein the modified oligonucleotide consists of 20 linked nucleosides.

35. (Currently Amended) The compound of claim 20 wherein the compound comprises a chimeric oligonucleotide compound selected from the group consisting of ISIS 134318, ISIS 134319, ISIS 134320, ISIS 134321, ISIS 134322, ISIS 134323 ~~to~~ and ISIS 134324.

36. (Currently Amended) The compound of claim 20 wherein the compound comprises a nucleobase sequence selected from the group consisting of SEQ ID NOs: 59, 60, 61, 62, 63, 64 and [[-]]65.

37. (Currently Amended) The compound of claim 20 wherein the compound consists of a nucleobase sequence selected from the group consisting of SEQ ID NOs: 59, 60, 61, 62, 63, 64 and [[-]]65.

38. (Previously Presented) A method of inhibiting the expression of BCL2-associated X protein in cells or tissues in vitro comprising contacting said cells or tissues with the compound of claim 20 such that expression of BCL2-associated X protein is inhibited.